Eli Lilly and Co (MIL:1LLY) Dividends Received


MIL:1LLY Eli Lilly and Co MIL:1LLY
76 GF Score
Price €1,037.40
GF Value €1,232.32
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

MIL:1LLY
76GF Score
Eli Lilly and Co MIL:1LLY
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (MIL:1LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,037.40 is trading 15.8% below its estimated GF Value™ of €1,232.32. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for MIL:1LLY:

  • Dividends Received:
  • GF Value™: €1,232.32 vs. price of €1,037.40 (15.8% below fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the MIL:1LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
76GF Score

Get the complete analysis for MIL:1LLY

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,037.40
Price
€1,232.32
GF Value